Every material Form 8-K Neumora Therapeutics, Inc. has filed with the SEC since July 27, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Neumora Therapeutics received a Nasdaq notice on October 26, 2026 that its common stock is below the $1.00 minimum bid price required for continued listing on the Nasdaq Global Select Market. The company has 180 calendar days, until April 26, 2027, to regain compliance, and the filing states there can be no assurance it will do so, which raises the risk of future delisting for shareholders.
Nasdaq notice received October 26, 2026 under Listing Rule 5450(a)(1) for the $1.00 minimum bid price
Compliance period runs 180 calendar days, until April 26, 2027
Regaining compliance requires a closing bid of at least $1.00 per share for ten consecutive business days
If not compliant, the company may need to apply to transfer to The Nasdaq Capital Market and may consider a reverse stock split
Neumora reported a second-quarter 2026 net loss of $43.1 million, down from $52.7 million a year earlier, as research and development and general and administrative expenses declined. On the same day, President Joshua Pinto became chief executive officer effective August 14, 2026, succeeding Paul L. Berns, who becomes Executive Chairperson. The company said its $116.8 million in cash and cash equivalents is expected to support operations into the third quarter of 2027.
Q2 2026 net loss was $43.1 million, compared with $52.7 million in Q2 2025.
R&D expense was $29.3 million (Q2 2025: $38.7 million); G&A expense was $12.9 million (Q2 2025: $15.3 million).
Joshua Pinto, Ph.D., succeeds Paul L. Berns as CEO effective August 14, 2026, and was appointed a Class III director.
Cash and cash equivalents were $116.8 million as of June 30, 2026, expected to fund operations into the third quarter of 2027.
Neumora Therapeutics said a repeat 13-week rat toxicology study of NMRA-215 showed no unexpected in-life adverse findings, after an earlier study had reported such findings in 5 of 142 animals. The company continues to believe the earlier findings were not related to NMRA-215 and plans to submit an IND application in the fourth quarter of 2026.
Repeat 13-week rat toxicology study in 162 animals showed no unexpected in-life adverse findings.
A for-cause audit of the earlier study found various discrepancies and a number of critical audit observations.
The company plans to submit an IND in the fourth quarter of 2026 and initiate a Phase 1 study by the end of 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Neumora Therapeutics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →